Gustavo Baldassarre

List of Publications by Year
in descending order

128 papers	5,662 citations	76326 40 h-index	82547 72 g-index
132 all docs	132 docs citations	132 times ranked	8210 citing authors

#	Article	IF	Citations
1	HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel. Cell Death and Disease, 2022, 13, 429.	6.3	2
2	Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB. Biomedicines, 2022, 10, 1306.	3.2	3
3	<scp>CDKN1B</scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. Journal of Pathology, 2021, 253, 234-245.	4.5	12
4	RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target. Medicinal Research Reviews, 2021, 41, 586-615.	10.5	6
5	HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Molecular Oncology, 2021, 15, 1005-1023.	4.6	8
6	Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. In Vivo, 2021, 35, 2941-2945.	1.3	5
7	A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas. Scientific Reports, 2021, 11, 502.	3.3	9
8	A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients. Journal of Experimental and Clinical Cancer Research, 2021, 40, 79.	8.6	19
9	miRâ€9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Molecular Medicine, 2021, 13, e12872.	6.9	15
10	Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. Cancers, 2021, 13, 3035.	3.7	12
11	COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). ESMO Open, 2021, 6, 100165.	4.5	4
12	p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. Cell Death and Disease, 2021, 12, 951.	6.3	6
13	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. Cancers, 2021, 13, 5152.	3.7	7
14	Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. Cancer Research, 2020, 80, 1064-1077.	0.9	49
15	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. Cells, 2020, 9, 6.	4.1	20
16	Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells. Cells, 2020, 9, 36.	4.1	8
17	Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2020, 10, 550185.	2.8	13
18	A new role for IDH1 in the control of ovarian cancer cells metabolism and senescence. Annals of Translational Medicine, 2020, 8, 780-780.	1.7	4

#	Article	IF	Citations
19	Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells. Oncogene, 2020, 39, 6370-6386.	5.9	14
20	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	4.1	17
21	Differential miRNAs expression pattern of irradiated breast cancer cell lines is correlated with radiation sensitivity. Scientific Reports, 2020, 10, 9054.	3.3	18
22	Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene, 2020, 39, 4390-4403.	5.9	37
23	Abstract 5270: HSP90 identified by a proteomic approach as druggable target to reverse platinum-resistance in ovarian cancer. , 2020, , .		0
24	Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine, 2019, 46, 79-93.	6.1	13
25	Multiplex staining depicts the immune infiltrate in colitis-induced colon cancer model. Scientific Reports, 2019, 9, 12645.	3.3	9
26	Pathologist second opinion significantly alters clinical management of pT1 endoscopically resected colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 665-668.	2.8	12
27	USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Science Advances, 2019, 5, eaav3235.	10.3	79
28	p27kip1 at the crossroad between actin and microtubule dynamics. Cell Division, 2019, 14, 2.	2.4	14
29	The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo. Molecular Cancer Therapeutics, 2019, 18, 482-493.	4.1	2
30	Stathmin Is Required for Normal Mouse Mammary Gland Development and Î”16HER2-Driven Tumorigenesis. Cancer Research, 2019, 79, 397-409.	0.9	19
31	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).. Journal of Clinical Oncology, 2019, 37, 5564-5564.	1.6	1
32	Abstract 3128: miR-9 expression regulates and predicts the response to EGFR inhibitors in head & neck squamous cell carcinoma. , 2019, , .		0
33	Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. OncoTargets and Therapy, 2018, Volume 11, 8945-8950.	2.0	4
34	STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context. International Journal of Molecular Sciences, 2018, 19, 2818.	4.1	33
35	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2512.	4.1	30
36	Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors. Frontiers in Endocrinology, 2018, 9, 393.	3.5	26

#	Article	IF	Citations
37	Abstract 1460: Stathmin regulates mammary gland morphogenesis and tumorigenesis. , 2018, , .		0
38	An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2017, 23, 3769-3780.	7.0	36
39	Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Scientific Reports, 2017, 7, 595.	3.3	22
40	Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Scientific Reports, 2017, 7, 7104.	3.3	28
41	CDK6 protects epithelial ovarian cancer from platinumâ€induced death via FOXO3 regulation. EMBO Molecular Medicine, 2017, 9, 1415-1433.	6.9	61
42	SRSF2 mutations in epithelial ovarian cancer. Cancer Breaking News, 2017, 5, 25-29.	0.0	2
43	Molecular biology of breast tumors and prognosis. F1000Research, 2016, 5, 711.	1.6	6
44	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	10.7	97
45	p27kip1: An all-round tumor suppressor. Molecular and Cellular Oncology, 2016, 3, e1141742.	0.7	0
46	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	5.9	63
47	Meet me in the cytoplasm: A role for p27Kip1in the control of H-Ras. Small GTPases, 2016, 7, 71-75.	1.6	3
48	SUMOylation regulates p27^{Kip1}stability and localization in response to TGFÎ². Journal of Molecular Cell Biology, 2016, 8, 17-30.	3.3	11
49	Abstract A02: CDK6 controls platinum sensitivity via the regulation of FOXO3a/ATR: A new actionable pathway for ovarian cancer patients.. , 2016, , .		1
50	Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer. Aging, 2016, 8, 958-977.	3.1	8
51	p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms. Oncotarget, 2016, 7, 64560-64574.	1.8	5
52	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	1.8	15
53	p27 ^{kip1} controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13916-13921.	7.1	45
54	Roles of CDKN1B in cancer?. Aging, 2015, 7, 529-530.	3.1	8

#	Article	IF	Citations
55	Mutant AKT1-E17K is oncogenic in lung epithelial cells. Oncotarget, 2015, 6, 39634-39650.	1.8	24
56	Time-tuning cancer therapy. Aging, 2015, 7, 531-532.	3.1	0
57	C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4209-4214.	7.1	140
58	Genetic characterization of p27^{kip1}and stathmin in controlling cell proliferation in vivo. Cell Cycle, 2014, 13, 3100-3111.	2.6	34
59	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	6.9	3
60	p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Molecular Oncology, 2014, 8, 766-780.	4.6	28
61	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. Journal of Ovarian Research, 2014, 7, 72.	3.0	12
62	LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Oncotarget, 2014, 5, 970-977.	1.8	21
63	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. Oncotarget, 2014, 5, 1185-1197.	1.8	17
64	Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. Oncotarget, 2014, 5, 6267-6279.	1.8	57
65	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	6.9	49
66	Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology, 2013, 5, 428-431.	3.3	19
67	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9845-9850.	7.1	176
68	Abstract B056: p70S6K activity drives local relapse in breast cancer. , 2013, , .		0
69	New light on p27^{kip1} in breast cancer. Cell Cycle, 2012, 11, 3701-3702.	2.6	18
70	Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. Journal of Cellular Physiology, 2012, 227, 233-238.	4.1	9
71	Stathmin Is Dispensable for Tumor Onset in Mice. PLoS ONE, 2012, 7, e45561.	2.5	10
72	Abstract 3043: A CDK-independent function of p27kip1 controls cell proliferation. , 2012, , .		0

#	Article	IF	Citations
73	Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1249-1266.	3.4	155
74	Role of T198 Modification in the Regulation of p27Kip1 Protein Stability and Function. PLoS ONE, 2011, 6, e17673.	2.5	45
75	Abstract 1419: Role of p70S6K in breast cancer recurrence. , 2011, , .		0
76	Abstract 332: B-Raf mutations are associated with a worse outcome in ovarian cancer. , 2011, , .		0
77	p27^{kip1} Controls Cell Morphology and Motility by Regulating Microtubule-Dependent Lipid Raft Recycling. Molecular and Cellular Biology, 2010, 30, 2229-2240.	2.3	68
78	Role of Glucocorticoids in Breast Cancer. Current Pharmaceutical Design, 2010, 16, 3593-3600.	1.9	22
79	The Tumor Suppressor Functions of p27^{kip1} Include Control of the Mesenchymal/Amoeboid Transition. Molecular and Cellular Biology, 2009, 29, 5031-5045.	2.3	60
80	Beneficial Effects of Intraoperative Radiotherapy on Tumor Microenvironment Could Improve Outcomes (Int J Radiat Oncol Biol Phys 2008;72:1575â€“1581). International Journal of Radiation Oncology Biology Physics, 2009, 74, 976.	0.8	17
81	MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer. Oncogene, 2009, 28, 257-269.	5.9	43
82	MicroRNAs: The Jack of All Trades. Clinical Leukemia, 2009, 3, 20-32.	0.2	2
83	E2F1-Regulated MicroRNAs Impair TGFÎ²-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	16.8	818
84	Somatostatin as a Regulator of First-Trimester Human Trophoblast Functions. Placenta, 2008, 29, 660-670.	1.5	4
85	p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Molecular Cancer Therapeutics, 2008, 7, 1164-1175.	4.1	49
86	Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding. Clinical Cancer Research, 2008, 14, 1325-1332.	7.0	200
87	Stathmin Activity Influences Sarcoma Cell Shape, Motility, and Metastatic Potential. Molecular Biology of the Cell, 2008, 19, 2003-2013.	2.1	121
88	Take Your "M" Time. Cell Cycle, 2007, 6, 2087-2090.	2.6	3
89	Fez1/Lzts1 a new mitotic regulator implicated in cancer development. Cell Division, 2007, 2, 24.	2.4	19
90	Fez1/Lzts1 Absence Impairs Cdk1/Cdc25C Interaction during Mitosis and Predisposes Mice to Cancer Development. Cancer Cell, 2007, 11, 275-289.	16.8	67

#	Article	IF	Citations
91	Prostaglandin E2 Inhibits Proliferation and Migration of HTR-8/SVneo Cells, a Human Trophoblast-derived Cell Line. Placenta, 2006, 27, 592-601.	1.5	43
92	Effects of PGE2 on Human Trophoblast Proliferation and Migration. Placenta, 2006, 27, 930-932.	1.5	0
93	Haploinsufficiency of the Hmga1 Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice. Cancer Research, 2006, 66, 2536-2543.	0.9	104
94	Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene, 2005, 24, 3427-3435.	5.9	137
95	HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene, 2005, 24, 6809-6819.	5.9	29
96	p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell, 2005, 7, 51-63.	16.8	259
97	p27kip1 Functional Regulation in Human Cancer: A Potential Target for Therapeutic Designs. Current Medicinal Chemistry, 2005, 12, 1589-1605.	2.4	66
98	Familial Cancer Associated with a Polymorphism inARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	27.0	119
99	Reduced E-cadherin expression contributes to the loss of p27 kip1 -mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis, 2005, 26, 1021-1034.	2.8	56
100	Linking Inflammation to Cell Cycle Progression. Current Pharmaceutical Design, 2004, 10, 1653-1666.	1.9	22
101	Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland. Oncogene, 2003, 22, 7576-7586.	5.9	23
102	Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma. Molecular and Cellular Biology, 2003, 23, 2225-2238.	2.3	119
103	Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors. Molecular and Cellular Biology, 2003, 23, 3774-3787.	2.3	58
104	Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation. FASEB Journal, 2003, 17, 1-27.	0.5	63
105	HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis, 2003, 24, 1191-1198.	2.8	75
106	FEZ1/LZTS1 Is Down-Regulated in High-Grade Bladder Cancer, and Its Restoration Suppresses Tumorigenicity in Transitional Cell Carcinoma Cells. American Journal of Pathology, 2002, 160, 1345-1352.	3.8	38
107	Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1. Oncogene, 2002, 21, 1739-1749.	5.9	13
108	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene, 2002, 21, 3190-3198.	5.9	201

#	Article	IF	Citations
109	A Truncated Form of Teratocarcinoma-Derived Growth Factor-1 (Cripto-1) mRNA Expressed in Human Colon Carcinoma Cell Lines and Tumors. Tumor Biology, 2001, 22, 286-293.	1.8	19
110	Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7970-7975.	7.1	92
111	FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10374-10379.	7.1	89
112	PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1. Oncogene, 2000, 19, 3146-3155.	5.9	139
113	Rat Protein Tyrosine Phosphatase Î· Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27 Kip1. Molecular and Cellular Biology, 2000, 20, 9236-9246.	2.3	99
114	Pivotal Role of the RB Family Proteins in in Vitro Thyroid Cell Transformation. Experimental Cell Research, 2000, 260, 257-267.	2.6	10
115	Assignment of human teratocarcinoma derived growth factor (TDGF) sequences to chromosomes 2q37, 3q22, 6p25 and 19q13.1. Cytogenetic and Genome Research, 1999, 84, 220-224.	1.1	11
116	Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes. European Journal of Endocrinology, 1999, 140, 597-607.	3.7	9
117	Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene, 1999, 18, 4860-4869.	5.9	51
118	Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. Oncogene, 1999, 18, 6241-6251.	5.9	43
119	Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation, 1999, 104, 865-874.	8.2	110
120	The RIÎ± subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor. Oncogene, 1997, 14, 923-928.	5.9	94
121	Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1. Oncogene, 1997, 15, 927-936.	5.9	60
122	Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. , 1996, 66, 538-543.		22
123	Differential effects of protein kinase a sub-units on chinese-hamster-ovary cell cycle and proliferation. International Journal of Cancer, 1994, 59, 712-716.	5.1	27
124	Down-regulation of riÎ± subunit of camp-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-ha-ras and c-erbb-2 proto-oncogenes. International Journal of Cancer, 1993, 53, 438-443.	5.1	46
125	Infection with a transforming growth factor Î± anti-sense retroviral expression vector reduces thein vitro growth and transformation of a human colon cancer cell line. International Journal of Cancer, 1993, 54, 952-958.	5.1	31
126	Reduction of RI? Subunit of cAMP-dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF-?, c-Ha-ras, and c-erbB-2 Genes. Annals of the New York Academy of Sciences, 1993, 698, 102-107.	3.8	4

#	Article	IF	Citations
127	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. , 0, .		1
128	CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Frontiers in Oncology, 0, 12, .	2.8	14